Article Information
History
- March 26, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Alexander P Bye1,2,
- Willianne Hoepel3,4,
- Joanne L Mitchell1,5,
- Sophie Jégouic2,
- Silvia Loureiro2,
- Tanya Sage1,2,
- Steven de Taeye6,
- Marit van Gils6,
- Neline Kriek1,2,
- Nichola Cooper7,
- Ian Jones2,
- Jeroen den Dunnen3,4 and
- Jonathan M Gibbins1,2,*
- 1Institute for Cardiovascular and Metabolic Research, University of Reading, Reading, United Kingdom
- 2School of Biological Sciences, University of Reading, UK
- 3Department of Rheumatology and Clinical Immunology, Amsterdam UMC, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands
- 4Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
- 5Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham
- 6Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Infection and Immunity Institute, Amsterdam, Netherlands
- 7Hammersmith Hospital, Imperial College London, London, UK
- ↵*Corresponding author; email: j.m.gibbins{at}reading.ac.uk
Posted March 26, 2021.
Aberrant glycosylation of anti-SARS-CoV-2 IgG is a pro-thrombotic stimulus for platelets
